Bruce R. Korf, MD, PhD
Associate Dean for Genomic Medicine, School of Medicine
Chief Genomics Officer, UAB Medicine
Wayne H. and Sara Crews Finley Endowed Chair in Medical Genetics
Professor of Genetics
Co-Director of the UAB-HudsonAlpha Center for Genomic Medicine
The University of Alabama at Birmingham
Birmingham, AL

Dr. Bruce R. Korf is the Associate Dean for Genomic Medicine, School of Medicine; Chief Genomics Officer, UAB Medicine; Wayne H. and Sara Crews Finley Endowed Chair in Medical Genetics, Professor of Genetics, Co-Director of the UAB-HudsonAlpha Center for Genomic Medicine, Associate Director for Rare Diseases, Hugh Kaul Personalized Medicine Institute and editor-in-chief of the American Journal of Human Genetics.  He is a medical geneticist, pediatrician, and child neurologist, certified by the American Board of Medical Genetics and Genomics (clinical genetics, clinical cytogenetics, and clinical molecular genetics), American Board of Pediatrics, and American Board of Psychiatry and Neurology (child neurology). Dr. Korf is past president of the Association of Professors of Human and Medical Genetics, past president of the American College of Medical Genetics and Genomics, and current president of the ACMG Foundation for Genetic and Genomic Medicine.  He has served on the Board of Scientific Counselors of the National Cancer Institute and the National Human Genome Research Institute at the NIH. His major research interests are molecular diagnosis of genetic disorders and the natural history, genetics, and treatment of neurofibromatosis.  He serves as principal investigator of the Department of Defense funded Neurofibromatosis Clinical Trials Consortium, the Alabama Genomic Health Initiative, and the Southern All of Us Network.  He is co-author of Human Genetics and Genomics (medical student textbook, now in fourth edition), Medical Genetics at a Glance (medical student textbook (now in third edition), Emery and Rimoin’s Principles and Practice of Medical Genetics (now in 6^th edition), and Current Protocols in Human Genetics.

Justin Jordan, MD, MPH
Neuro-Oncologist
Clinical Director, MGH Pappas
Center for Neuro-Oncology
Director, Family Center for Neurofibromatosis
Massachusetts General Hospital
Boston, MA

Dr. Jordan is an assistant professor of neurology at Harvard Medical School and serves as the Director of the Family Center for Neurofibromatosis and as the Clinical Director for Neuro-Oncology at Massachusetts General Hospital. In addition to his clinical work, Dr. Jordan is involved in both translational and clinical research, including serving as site PI for the national Neurofibromatosis Clinical Trials Consortium. He is a leader in multiple national organizations, currently serving as a member of the Children’s Tumor Foundation Clinical Care Advisory Committee, vice chair of the Health Policy Subcommittee of American Academy of Neurology (AAN), member of the guidelines committee of the Society for Neuro-Oncology, and several other roles.

In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planner:
Vanessa Carranza, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Bruce R. Korf, MD, PhD– has disclosed he is a consultant for Genome Medical and SpringWorks Therapeutics. He has fiduciary responsibility with ACMG Foundation and receives grant/research support from AstraZeneca. 

Authors/Presenters:
Bruce R. Korf, MD, PhD– has disclosed he is a consultant for Genome Medical and SpringWorks Therapeutics. He has fiduciary responsibility with ACMG Foundation and receives grant/research support from AstraZeneca. 
Justin Jordan, MD, MPH– has disclosed he is a consultant for Navio Theragnostics and CereXis. 

Reviewer: Disclosure to come